Related Experiment Video
Updated: Feb 20, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
Ahmet Emre Eskazan1, Dilek Keskin2
1Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Kocamustafapasa/Fatih, 34303 Istanbul, Turkey.
Abstract:
Although imatinib has dramatically improved major outcomes in patients with chronic myeloid leukemia (CML), there are newer tyrosine kinase inhibitors (TKIs) approved worldwide for the treatment of resistant cases, and two second-generation TKIs (dasatinib, nilotinib) are approved in some nations for treating patients in the upfront setting. Radotinib (IY5511HCL, Supect®) is a novel and selective second-generation BCR-ABL1 TKI, which is currently approved in Korea for the treatment of patients with CML both in the upfront and salvage settings. This review mainly focuses on the clinical potential of radotinib in patients with CML in chronic phase in terms of efficacy and safety.
Insights
Radotinib is a novel second-generation tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML). This review explores its efficacy and safety in CML patients, offering a new treatment option.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Imatinib has improved chronic myeloid leukemia (CML) outcomes.
- Newer tyrosine kinase inhibitors (TKIs) address resistance and upfront treatment.
- Radotinib is a selective second-generation BCR-ABL1 TKI approved in Korea.
Purpose of the Study:
- To review the clinical potential of radotinib.
- Focus on efficacy and safety in chronic phase CML patients.
- Evaluate radotinib as a treatment option for CML.
Main Methods:
- Literature review of clinical studies on radotinib.
- Analysis of efficacy data in CML patients.
- Assessment of safety and tolerability profiles.
Main Results:
- Radotinib demonstrates clinical potential in CML treatment.
- Efficacy data suggests effectiveness in chronic phase CML.
- Safety profile is being evaluated for broader application.
Conclusions:
- Radotinib shows promise as a second-generation TKI for CML.
- Further evaluation of its efficacy and safety is warranted.
- Radotinib may offer a valuable therapeutic option for CML patients.
